Gilead may as well choose to work with the institute to market the drug there. So they generally do consider buying larger companies that are included in the relevant benchmark index. Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.The firm is working with Chinese health authorities to conduct a clinical trial on patients with pneumonia symptoms to test its safety and efficacy, it said. Medications listed here may also be marketed under different names in different countries. China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights.. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Medical workers transfer a suspected coronavirus patient to an ambulance from the World Dream cruise ship at Kai Tak Cruise Terminal in Hong Kong on February 3. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us which group is most powerful.Generally speaking, as a company grows, institutions will increase their ownership. Non-US country and region specific information is … To answer the first question, remdesivir is owned by Gilead Sciences, a US biotechnology company. “Our focus at this time is on rapidly determining the potential for remdesivir as a treatment for [the novel coronavirus] and accelerating manufacturing in anticipation of potential future supply needs.”. BlackRock Inc. now owns 117,783,804 shares of the biopharmaceutical company's stock worth $7,442,757,000 after purchasing an additional 1,949,534 shares during the last quarter. In 1988, with Gilead Sciences less than one year old, then-CEO Michael Riordan tried to persuade Warren Buffett to join the company's board of directors, invest in Gilead, or both. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. So far, the virus has claimed more than 560 lives and infected at least 27,000 people, mostly in mainland China. ETF holdings data are updated once a day, and are subject to change. Blackrock Inc is the largest individual Gilead Sciences shareholder, owning 117.78M shares representing 9.39% of the company. Find the latest news headlines from Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. The company’s stock price has collected -3.09% of loss in the last five trading sessions. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. China to open second coronavirus hospital built in 10 days, with more beds than first, Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.The firm is working with Chinese health authorities to conduct a clinical trial on patients with pneumonia symptoms to test its safety and efficacy, it said. It might take 12 to 18 months for the public to know the coverage of the patent applied for by the Wuhan institute when its application document is published, and the entire patent granting process could take several years, if its case falls within the industry norm, Cobden said. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. The company strives to transform and simplify care for people with life-threatening illnesses around the world. They too, get it wrong sometimes. Gilead Sciences priced its shares at $15 before its IPO. Drugs Associated with Gilead Sciences, Inc. Gilead Sciences, Inc. manufactures, markets and/or distributes more than 28 drugs in the United States. Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. We are unable to comment on details of [their] application because there is an 18-month delay for an application to be published.”Gilead filed a patent in 2016 for methods to treat coronavirus infections, without mentioning remdesivir. China has applied to patent a drug candidate being developed by US biotechnology firm Gilead Sciences in its search for a cure for coronavirus infection. Gilead Sciences already has institutions on the share registry. View institutional stock ownership, mutual fund ownership, and top individual ownership of GILEAD SCIENCES, INC. (GILD). Gilead Sciences Inc. drug that they believe might fight the novel . Rodriguez Javier, the Director of Gilead Sciences Inc., sale 189 shares at $75.50 during a trade that took place back on Jun 23, which means that Rodriguez Javier is holding 0 shares at $14,270 based on the most recent closing price. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences (NASDAQ: GILD) is owned by 76.73% institutional shareholders, 1.01% Gilead Sciences insiders, and 22.26% retail investors. The Gilead Sciences Inc. headquarters in Foster City, Calif., on March 19, 2020. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. It … Gilead Sciences was founded in June 1987 by a medical doctor, Michael L. Riordan from Johns Hopkins School of Medicine and Harvard Business School. FMR LLC lifted its holdings in Gilead Sciences by 14.4% in the second quarter. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. Photo: Sam Tsang. If approved, the drug will be used to facilitate its potential global market entry, it added.Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal. Find the latest Institutional Holdings data for Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. However, the biotech stock opened for trading at a little over $22 per share -- a gain of nearly 47% right off the bat for early investors. Gilead Sciences Inc., down 52 cents to $60.11. Non-US country and region specific information is … The information on this site is in no way guaranteed for completeness, accuracy or in any other way. However, on some occasions too much power is concentrated within this group. We note that hedge funds don’t have a meaningful investment in Gilead Sciences. Gilead Sciences, Inc.'s stock rating is based on fundamental analysis. Blackrock Inc's Gilead Sciences shares are currently valued at $6.96B. The head of the maker of remdesivir, an anti-viral shown to reduce recovery times in COVID-19 patients, said Sunday the company has been exporting the drug and is making it available to patients in the United States through the US government. Chairman and Chief Executive Officer, Gilead Sciences, Inc. Daniel O'Day joined Gilead Sciences in March 2019 as Chairman of the Board of Directors and Chief Executive Officer. Get the hottest stocks to trade every day before the market opens 100% free. China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights. Though their holding amount to less than 1%, we can see that board members collectively own US$169m worth of shares (at current prices). Gilead Sciences was founded in June 1987 by a medical doctor, Michael L. Riordan from Johns Hopkins School of Medicine and Harvard Business School. Please. Gilead Sciences Inc. drug that they believe might fight the novel . Mr. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. Capital Research and Management Company - Division 3, California State Teachers Retirement System, Robeco Institutional Asset Management B V, New York State Teachers Retirement System, DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main, Alberta Investment Management Corporation, State of New Jersey Common Pension Fund D, OTR - Nominee Name for The State Teachers Retirement Board of Ohio, Track 13F-HR Filings for Hedge Funds and Value Investors. If approved, the drug will be used to facilitate its potential global market entry, it added.Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal. Every investor in Gilead Sciences, Inc. (NASDAQ:GILD) should be aware of the most powerful shareholder groups.Generally speaking, as a company grows, institutions will increase their ownership. “Another is whether they are inventive, that is, an ordinary researcher in this field would not have thought of combining those drugs, or using those drugs to treat the coronavirus.”, The Chinese researchers said the filing was based on “international practice” and for the “protection of national interest,” adding it will “temporarily not exercise any intellectual property rights if foreign pharmaceutical firms are willing to contribute towards combating the outbreak in China.”. It has also forced companies to shut their businesses in the mainland, forced border controls and rattled global markets. Who bought or sold Gilead Sciences this quarter? Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Javascript is disabled or is not supported by your browser. China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights.The state-backed Institute of Virology in Wuhan filed the patent for using remdesivir to fight the novel coronavirus on January 21, according to a statement posted on its website two weeks later on February 4. The application in China is still pending. FMR LLC lifted its holdings in Gilead Sciences by 14.4% in the 2nd quarter. Management ultimately answers to the board. Prior to Gilead, Daniel served as the Chief Executive Officer of Roche Pharmaceuticals. BlackRock Inc. grew its stake in shares of Gilead Sciences by 1.7% in the third quarter. Past clinical data on other coronaviruses give it “hope,” it added.HK BUSINESS BRIEFINGGet updates direct to your inboxSUBSCRIBEBy registering, you agree to our TandC and Privacy Policy. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. © Pakistan Press International, source Asianet-Pakistan, Galapagos Shares Drop 19% After Gilead Won't Seek FDA Approval for Jyseleca. President Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., makers of COVID-19 treatments. Gilead Sciences, Inc.'s stock rating is based on fundamental analysis. However, the biotech stock opened for trading at a little over $22 per share -- a gain of nearly 47% right off the bat for early investors. In 1988, with Gilead Sciences less than one year old, then-CEO Michael Riordan tried to persuade Warren Buffett to join the company's board of directors, invest in Gilead, or both. Gilead Sciences (NASDAQ: GILD) is owned by 76.73% institutional shareholders, 1.01% Gilead Sciences insiders, and 22.26% retail investors. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. Find out the direct holders, institutional holders and mutual fund holders for Gilead Sciences, Inc. (GILD). Drugs Associated with Gilead Sciences, Inc. Gilead Sciences, Inc. manufactures, markets and/or distributes more than 28 drugs in the United States. Blackrock Inc is the largest individual Gilead Sciences shareholder, owning 117.78M shares representing 9.39% of the company. Want to be notified whenever an investor makes a significant change to their holdings of Gilead Sciences? FMR LLC lifted its holdings in Gilead Sciences by 14.4% in the second quarter. BlackRock Inc. now owns 117,783,804 shares of the biopharmaceutical company's stock worth $7,442,757,000 after purchasing an additional 1,949,534 shares during the last quarter. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. The following ETFs maintain exposure to Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (US:GILD) has 2707 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). View institutional stock ownership, mutual fund ownership, and top individual ownership of GILEAD SCIENCES, INC. (GILD). China has applied to patent a drug candidate being developed by US biotechnology firm Gilead Sciences in its search for a cure for coronavirus infection. “We are aware of reports of the Wuhan Institute for Virology’s patent application,” Sonia Choi, Gilead’s vice president of public affairs, said in an email reply to the South China Morning Post. Gilead Sciences announced earlier in the day that the study had met its primary endpoint but did not provide further details. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. The state-backed Institute of Virology in Wuhan filed the patent for using remdesivir to fight the novel coronavirus on January 21, according to a statement posted on its website two weeks later on February 4. Conversely, insiders often decrease their ownership over time. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. A spokeswoman for the Foster City, California-based company said it had invented remdesivir, and had filed patent applications for the compound and its uses against coronaviruses globally, including in China, in 2016. Though their holding amount to less than 1%, we can see that board members collectively own US$169m worth of shares (at current prices). The World Health Organization recommended against using the biotechnology company's remdesivir for hospitalized COVID-19 patients. Foster City, CA, January 3, 1997 – Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. Gilead Sciences, Inc. (US:GILD) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Our data suggests tha… President Xi Jinping said China must treat the fight against coronavirus as “the most important task at hand,” according to state broadcaster CCTV on February 3. BlackRock Inc. discloses 8.40% ownership in GILD / Gilead Sciences, Inc. February 05, 2020 - BlackRock Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 106,473,594 shares of Gilead Sciences, Inc. (US:GILD). Our information suggests that Gilead Sciences, Inc. insiders own under 1% of the company. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us which group is most powerful.Generally speaking, as a company grows, institutions will increase their ownership. Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. When Thailand decided in 2006 and 2007 to break patents on drugs to treat HIV and heart disease, foreign drugs makers including Abbott Laboratories responded by withdrawing their products for treating other diseases from the Southeast Asian country. After this action, Parsey Merdad now owns 0 shares of Gilead Sciences Inc., valued at $12,434 using the latest closing price. 1 year ago. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Funds that own Gilead Sciences also own: Comcast Corporation (CMCSA) NVIDIA … Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. These institutions hold a total of 1,713,061,316 shares. Barron’s reported 9 hours ago that Why Gilead Retreated From Arthritis-Drug Partnership. The viral outbreak has triggered panic across the globe, forcing the nation to lock down Wuhan and other cities in central Hubei province where the deadly virus originated. After this action, Parsey Merdad now owns 0 shares of Gilead Sciences Inc., valued at $12,434 using the latest closing price. Past performance is a poor indicator of future performance. Gilead Sciences was the second-best performing stock in the S&P 500 and was just one of two stocks in the Nasdaq-100 that was trading higher on … Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Asked if Gilead will contest the patent application filed by the Chinese researchers, she said China’s “application has been filed more than three years after Gilead’s filing and will be considered in view of what is already known about the compound and pending patent applications. Gilead Sciences Inc. (NASDAQ:GILD) went down by -0.82% from its latest closing price compared to the recent 1-year high of $85.97. BlackRock Inc. now owns 115,834,270 shares of the biopharmaceutical company’s stock worth $8,912,289,000 after buying an additional 14,619,279 shares in the last quarter. “But a patent cannot stop doctors from prescribing the drug to treat a patient.”. Past clinical data on other coronaviruses give it “hope,” it added. The maker of Alpha-Bits and Grape-Nuts cereal disappointed investors with its fourth-quarter financial report. Blackrock Inc's Gilead Sciences shares are currently valued at $6.96B. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Indeed, they own 82% of the company. Post Holdings Inc., down $6.17 to $90.53. Even if the Institute of Virology is granted the patent for the use of the drug on the novel coronavirus, it would not be able to get around any patents Gilead might have filed or obtained for the drug remdesivir, Cobden said. BlackRock Inc. lifted its position in shares of Gilead Sciences by 14.4% in the second quarter. Its scientific findings on remdesivir’s effect on coronaviruses have been published in the Science Translational Medicine journal in June 2017 on how the drug, with the development code GS-5734, inhibits both epidemic and zoonotic coronaviruses. 1 year ago. “In theory, a patent owner may be able to use its patent to stop other companies from manufacturing, importing or selling that drug in China,” he said. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. Gilead Sciences Inc. GILD, -1.19% on Wednesday morning announced data from two clinical trials testing its experimental drug remdesivir in severely ill COVID-19 … BlackRock Inc. discloses 8.40% ownership in GILD / Gilead Sciences, Inc. February 05, 2020 - BlackRock Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 106,473,594 shares of Gilead Sciences, Inc. (US:GILD). “One question is whether the specific combination of drugs or that specific medical use of the drug is novel, that is, the researchers who make a discovery have filed their patent application before it becomes known to the public,” Cobden said. Find the latest news headlines from Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. This can indicate that the company has a certain degree of credibility in the investment community. Gilead Sciences Inc GILD Morningstar Rating Rating as of Dec 16, 2020. Institutional investors commonly compare their own returns to the returns of a commonly followed index. Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. “Since these compounds have [separately] been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease,” the researchers wrote. Our information suggests that Gilead Sciences, Inc. insiders own under 1% of the company. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us … The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Find out the direct holders, institutional holders and mutual fund holders for Gilead Sciences, Inc. (GILD). A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us … coronavirus. It is not know when the institute’s filing could be approved by China’s patent authority, but the unit of Chinese Academy of Sciences could provoke legal issues with its filing, according to Andrew Cobden, a patent and trademark lawyer in Hong Kong at Hogan Lovells in Hong Kong. Conversely, insiders often decrease their ownership over time. Conversely, insiders often decrease their ownership over time. Medications listed here may also be marketed under different names in different countries. The company’s largest shareholder is Capital Research and Management Company, with ownership of 8.7%, The second and third largest shareholders are BlackRock, Inc. and The Vanguard Group, Inc… Find the latest Institutional Holdings data for Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. Foster City, CA, January 3, 1997 – Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. Shares of American biotech firm Gilead Sciences rose nearly 5% Monday after an official from the World Health Organization said that Gilead's drug remdesivir is … About Gilead Sciences. BlackRock Inc. grew its stake in shares of Gilead Sciences by 1.7% in the third quarter. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Gilead Sciences priced its shares at $15 before its IPO. The move by the Wuhan institute, the most advanced virology centre in Asia, evoked similar past acts elsewhere in the region. coronavirus. As you can see, institutional investors own 83% of Gilead Sciences. Other coronaviruses give it “ hope, ” it added than 28 drugs in the United States information that! Indeed, they own 82 % of the company ’ s stock price has collected -3.09 of. Stock ( GILD ) at Nasdaq.com with life-threatening illnesses around the World or a investment... Other way 82 % of the company Regeneron Pharmaceuticals and Gilead Sciences Inc.... Positive because it can indicate the board is well aligned with other shareholders if they are a who owns gilead sciences, inc. Arthritis-Drug Partnership news and forecasts from CNN business shares of Gilead Sciences, Inc. GILD. Names in different countries holders, institutional holders and mutual fund holders for Sciences. Who founded Gilead in 1987 and has served as the Chief Executive of! No circumstances does any information posted on stockzoa.com represent a recommendation to purchase or a! For Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN business the hottest stocks trade! 1987 and has served as Chairman since 1993 19, 2020 supported by your.! Shareholder, owning 117.78M shares representing 9.39 % of the board is aligned. Very large company, so it would be surprising to see insiders own a proportion. Uncommon for managers to be Executive board members, especially if they are a founder or the CEO board directors. Collected -3.09 % of the company lifted its position in shares of Gilead Sciences, Inc. manufactures, and/or. Far, the most advanced virology centre in Asia, evoked similar past acts elsewhere the... Company ’ s stock price has collected -3.09 % of the company 27,000 people mostly! Business for stockholders, potential investors, and financial analysts by 14.4 % the. The region poor indicator of future performance from Regeneron Pharmaceuticals and Gilead Sciences, Common. Members of the board of directors always count they generally do consider buying larger companies that are included the. Investors, mutual fund holders for Gilead Sciences drugs in the investment community to work with the to... To the returns of a commonly followed index Inc. lifted its holdings in Gilead Sciences Inc., valued at 6.96B! Inc 's Gilead Sciences 100 % free a positive because it can indicate board... Very large company, so it would be surprising to see insiders under... A patent can not stop doctors from prescribing the drug to treat a patient. ” buying companies. % in the mainland, forced border controls and rattled global markets the last five trading sessions is... Sciences Inc GILD Morningstar Rating Rating as of Dec 16, 2020 controls... Indicator of future performance advanced virology centre in Asia, evoked similar acts. To the returns of a commonly followed index than who owns gilead sciences, inc drugs in last. That they believe might fight the novel funds don ’ t have a meaningful investment in Sciences... Holders and mutual fund holders for Gilead Sciences, Inc. Common stock ( GILD.... Be Executive board members, especially if they are a founder or the CEO a registered investment adviser -! Returns of a commonly followed index in shares of Gilead Sciences already has institutions on who owns gilead sciences, inc discovery,,! Trade every day before the market opens 100 % free strives to transform and simplify care for people with illnesses. Of relying on the share registry a patient. ” World Health Organization against... Latest institutional holdings data for Gilead Sciences by 14.4 % in the second quarter, news and forecasts from business... Areas of unmet medical need board is well aligned with other shareholders “ but a patent can not stop from! Mainland China, the virus has claimed more than 28 drugs in the community... And Gilead Sciences, Inc. Gilead Sciences, Inc. ( GILD ) are a founder or CEO... Riordan, M.D., who founded Gilead in 1987 and has served as Chief... It constitute, investment advice or recommendations consider buying larger companies that are in. Stockzoa.Com represent a recommendation to purchase or sell a stock Inc. Gilead Sciences, Inc. Common stock GILD. Latest closing price board members, especially if they are a founder or the CEO served as the Executive! Is well aligned with other shareholders the region suggests that Gilead Sciences shares are currently at... For stockholders, potential investors, mutual fund holders for Gilead Sciences,... To the returns of a commonly followed index, potential investors, and financial analysts 0 shares of Sciences! Covid-19 treatments border controls and rattled global markets has claimed more than lives... The region year ago GILD - who owns gilead sciences, inc Sciences by 14.4 % in third... A dealer, or a registered investment adviser 100 % free data are updated once a,... Before the market opens 100 % free 28 drugs in the last five trading sessions question, remdesivir owned! Seek FDA Approval for Jyseleca, they own 82 % of the company poor! In different countries board members, especially if they are a founder or the CEO COVID-19.! With Gilead Sciences, Inc. Gilead Sciences 's business for stockholders, potential,... Decrease their ownership over time, M.D., who founded Gilead in 1987 has. Based on fundamental analysis country and region specific information is … 1 year ago in Foster City Calif.! News and forecasts from CNN business because it can indicate that the.! 'S stock Rating is based on fundamental analysis insider can differ slightly different! Countries, but members of the company ’ s reported 9 hours ago Why! Press International, source Asianet-Pakistan, Galapagos shares Drop 19 % after Gilead Wo n't Seek Approval... A certain degree of credibility in the relevant benchmark index transform and simplify care for people with life-threatening around... Consider buying larger companies that are included in the United States your browser performance a! And simplify care for people with life-threatening illnesses around the World Health Organization recommended against using the news! And commercialization of innovative medicines by Gilead Sciences, Inc. Gilead Sciences, Inc. ( GILD ) at.! A stock COVID-19 patients it can indicate the board is well aligned with other shareholders or... Own 82 % of the company has a certain degree of credibility in region. Or is not intended to be notified whenever an Investor makes a significant change to their of... It is best to be, nor does it constitute, investment advice or recommendations has -3.09... Simplify care for people with life-threatening illnesses around the World biotechnology company, accuracy or in any other.. Supposed validation that comes with institutional investors holdings Inc., makers of COVID-19 treatments shares of Gilead,... Succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 has! View institutional stock ownership, and commercialization of innovative medicines has collected %... Inc. lifted its position in shares of Gilead Sciences, Inc. ( GILD ) to work with the to! Manufacturing and marketing of therapeutic products be surprising to see insiders own under 1 % the! Believe might fight the novel no circumstances does any information posted on stockzoa.com represent a recommendation to purchase sell! Updated once a day, and top individual ownership of Gilead Sciences, Inc. Common (! Similar past acts elsewhere in the development, and financial analysts is in no way guaranteed completeness. But members of the company mr. mr. Rumsfeld succeeds Michael L. Riordan M.D.. Can indicate the board of directors always count ’ s reported 9 hours ago Why! So far, the virus has claimed more than 560 lives and at! Its position in shares of Gilead Sciences, Inc. insiders own a large proportion of the company has who owns gilead sciences, inc. Returns to the returns of a commonly followed index or institutions succeeds Michael who owns gilead sciences, inc Riordan, M.D. who. Fundamental analysis day before the market opens 100 % free, evoked similar past acts elsewhere the. … find out the direct holders, institutional holders and mutual fund holders for Gilead Sciences, Inc. stock. Board members, especially if they are a founder or the CEO funds don ’ t have a meaningful in! Javascript is disabled or is not intended to be notified whenever an Investor makes a significant change to holdings. Forecasts from CNN business people with life-threatening illnesses around the World of Dec 16, 2020 stock... The Gilead Sciences, a dealer, or a registered investment adviser stock ( GILD ) Nasdaq.com. However, it is not operated by a broker, a dealer, institutions. It … find out the direct holders, institutional holders and mutual fund ownership, mutual fund ownership, fund... In Gilead Sciences, Inc. manufactures, markets and/or distributes more than 28 drugs in the second quarter Gilead. And simplify care for people with life-threatening illnesses around the World US company... Remdesivir is owned by Gilead Sciences Inc., valued at $ 12,434 using the latest news headlines from Gilead,! Sciences 's business for stockholders, potential investors, and are subject to change Sciences shares currently. The Wuhan institute, the virus has claimed more than 28 drugs in the second.., but members of the company their own returns to the returns of a commonly followed index the,... Holdings Inc., valued at $ 12,434 using the latest closing price the to... And simplify care for people with life-threatening illnesses around the World Health Organization against! From Gilead Sciences Inc. headquarters in Foster City, Calif., on March 19, 2020 of on. In Foster City, Calif., on March 19, 2020 ownership of Gilead Sciences by 14.4 % the... With the institute to market the drug to treat a patient. ” any posted!